MSH6 and pure red-cell aplasia: When comparing clinicopathological characteristics of the patients harboring the deleterious/”potentially pathogenic” mutations (n = 18; excluding the cases with the MSH2 and MSH6 VUS, described above) with the “negative” group (n = 103), no statistically significant associations were observed, either considering all cases or considering the subgroups of cases with familial/hereditary PrCa or early-onset PrCa (S5 Table).